检索结果-南通市图书馆

Sex bias in response to hepatitis B vaccination in end-stage renal disease patients:Meta-analysis

World Journal of Nephrology 2016年第1期5卷 115-124页

作者： Hossein Khedmat aghdas aghaei Mohammad Ebrahim Ghamar-Chehreh Shahram Agah Baqiyatallah Research Center for Gastroen- terology and Liver Disease Baqiyatallah University of Medical Sciences Colorectal Research Center Iran University of Medical Sciences

AIM： To systematically review the literature for studies investigating the potential effect of gender of dialysis patients on the immunogenicity of hepatitis B virus vaccines. METHODS： Literature searches were conducted by the MEDLINE and Google Scholar. The key words used included “hepatitis B （HB）”, “vaccine”, “dialysis”, “hemodialysis”, “sex”, “male” and “female”. Data of seroresponse to HB vaccine in clinical trials regarding sex of the recipients have been achieved and analyzed. Finally data from 19 clinical trials have been pooled and ***： Analysis of response to HB vaccination in our dialysis population showed males significantly res-pond less to hepatitis B vaccination （P = 0.002, Z = 3.08） with no significant heterogeneity detected [P = 0.766; heterogeneity χ2 = 14.30 （df = 19）; I2 = 0%]. A reanalysis of the pooled data was conducted regarding the dialysis mode to evaluate potential differential impact of sex on HB vaccine response. Hemodialysis was the only subgroup that showed a signifcant difference regarding dialysis mode in response to HB vaccination regarding sex （ P = 0.042, Z = 2.03）.CONCLUSION： This Meta-analysis showed significant effect for the sex of chronic kidney disease and dialysis patients on the immunogenicity of HB vaccine. This sex discrimination was most prominent among hemodialysis patients.

关键词： Hepatitis B virus vaccination Hepatitis B virus Immunogenicity Dialysis patients Gender Sex

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cost-effectiveness of remdesivir for the treatment of hospitalized patients with COVID-19:a systematic review

引用

Infectious Diseases of Poverty 2023年第2期12卷 112-112页

作者： Aziz Rezapour Zahra Behroozi Mostafa Nasirzadeh Mohsen Rezaeian Mohammad Barzegar Mahsa Tashakori-Miyanroudi Abdollah Sayyad aghdas Souresrafil Health Management and Economics Research Center Health Management Research InstituteIran University of Medical SciencesTehranIran Physiology Research Center Institute of NeuropharmacologyKerman University of Medical SciencesKermanIran Department of Health Education and Health Promotion School of HealthOccupational Environment Research CenterRafsanjan University of Medical SciencesRafsanjanIran Department of Epidemiology and Biostatistics School of MedicineOccupational Environment Research CenterRafsanjan University of Medical SciencesRafsanjanIran Department of English Language Teaching School of Health Management and Information SciencesIran University of Medical SciencesTehranIran Psychiatry and Behavioral Sciences Research Center Addiction InstituteMazandaran University of Medical SciencesSariIran Department of Health Services and Health Promotion School of HealthOccupational Environment Research CenterRafsanjan University of Medical SciencesRafsanjanIran

Background Remdesivir is being studied and used to treat coronavirus disease 2019(COVID-19).This study aimed to systematically identify,critically evaluate,and summarize the findings of the studies on the cost-effectiveness of remdesivir in the treatment of hospitalized patients with *** In this systematic review,PubMed,EMBASE,Web of Science,SCOPUS,and the Cochrane Library were searched for studies published between 2019 and *** included all full economic evaluations of remdesivir for the treatment of hospitalized patients with *** were summarized in a structured and narrative *** Out of 616 articles obtained in this literature search,12 studies were included in the final *** mean score of the Quality of Health Economic Studies(QHES)for the studies was 87.66(high quality).All studies were conducted in high-income countries(eight studies in the USA and one study in England),except for three studies from middle-to-high-income countries(China,South Africa,and Turkey).Six studies conducted their economic analysis in terms of a health system perspective;five studies conducted their economic analysis from a payer perspective;three studies from the perspective of a health care *** results of five studies showed that remdesivir was cost-effective compared to standard ***,the therapeutic strategy of combining remdesivir with baricitinib was cost-effective compared to remdesivir *** Based on the results of the present study,remdesivir appears to be cost-effective in comparison with the standard of care in China,Turkey,and South *** conducted in the United States show conflicting results,and combining remdesivir with baricitinib is cost-effective compared with remdesivir ***,the cost-effectiveness of remdesivir in low-income countries remains ***,more studies in different countries are required to determine the cost-effectiveness of this drug.

关键词： Cost-effectiveness Remdesivir COVID-19 SARS-CoV-2

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：